News BridgeBio gets EU nod for ATTR cardiomyopathy drug BridgeBio and Bayer are poised to challenge Pfizer's Vyndaqel in the EU after acoramidis gets a green light for ATTR cardiomyopathy.
News FDA clears new antibiotic for superbug infections AbbVie has won FDA approval for Emblaveo, a new antibiotic to treat pathogens that pose serious public health threats.
News GSK rides out vaccine sales weakness with cancer, HIV gains Despite a steep fall-off in sales of RSV vaccine Arexvy last year, GSK has raised its long-term sales forecast to £40 billion in 2031.
News Pfizer builds on Braftovi bowel cancer OK with survival data Pfizer's Braftovi - just approved by the FDA as a first-line treatment for colorectal cancer based on response data - also extends patient survival.
News Pfizer offers $60m to settle prescriber kickback claims Pfizer has paid $60m to settle US government allegations that its Biohaven unit made improper payments to prescribers of its migraine drug Nurtec ODT.
Digital In conversation at Veeva Summit: Jonathan Crowther, Pfizer At the Veeva Commercial Summit in Madrid at the end of 2024, pharmaphorum web editor Nicole Raleigh sat down with Pfizer’s head of predictive analytics, Jonathan Crowther, to discuss the ro
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
